For research use only. Not for therapeutic Use.
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively[1].
MMPI-1154 (1-100 μM) inhibits MMP-2 enzyme isolated from rat heart in vitro, and 100% inhibition appears at the concentraction 100 μM[1].MMPI-1154 (1 μM) shows significant cardio-cytoprotecion, significantly decreases infarct size in an ex vivo model for acute myocardial infarction[1].
| Catalog Number | I015367 |
| CAS Number | 1382722-47-5 |
| Synonyms | 2-[[(4-fluorophenyl)methyl-[(4-phenylmethoxyphenyl)methyl]amino]methyl]-1H-imidazole-5-carboxylic acid |
| Molecular Formula | C26H24FN3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H24FN3O3/c27-22-10-6-19(7-11-22)15-30(17-25-28-14-24(29-25)26(31)32)16-20-8-12-23(13-9-20)33-18-21-4-2-1-3-5-21/h1-14H,15-18H2,(H,28,29)(H,31,32) |
| InChIKey | QLTNFRCPUOPISS-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)COC2=CC=C(C=C2)CN(CC3=CC=C(C=C3)F)CC4=NC=C(N4)C(=O)O |
| Reference | [1]. Péter Bencsik, et al. Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection.Front Pharmacol. 2018 Apr 5;9:296. |
